Anticoagulation strategies in continuous renal replacement therapy.
anticoagulation
citrate
continuous renal replacement therapy
Journal
Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
21
01
2021
received:
23
12
2020
accepted:
23
01
2021
pubmed:
9
3
2021
medline:
15
3
2022
entrez:
8
3
2021
Statut:
ppublish
Résumé
The most common anticoagulant options for continuous renal replacement therapy (CRRT) include unfractionated heparin (UFH), regional citrate anticoagulation (RCA), and no anticoagulation. Less common anticoagulation options include UFH with protamine reversal, low-molecular weight heparin (LMWH), thrombin antagonists, and platelet inhibiting agents. The choice of anticoagulant for CRRT should be determined by patient characteristics, local expertise, and ease of monitoring. The Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury guidelines recommend using RCA rather than UFH in patients who do not have contraindications to citrate and are with or without increased risk of bleeding. Monitoring should include evaluation of the anticoagulant effect, circuit life, filter efficacy, and complications.
Substances chimiques
Anticoagulants
0
Heparin, Low-Molecular-Weight
0
Heparin
9005-49-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-422Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Schetz M. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol. 2001;132:283-303.
Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature. 1973;246(5432):355-357.
Greaves M. Control of Anticoagulation Subcommittee of the S, Standardization Committee of the International Society of T, Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost. 2002;87(1):163-164.
Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S-94S.
Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157(21):2475-2479.
van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol. 1996;7(1):145-150.
Ostermann M, Dickie H, Tovey L, Treacher D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care. 2010;14(3):419.
Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. 1999;27(10):2224-2228.
de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Crit Care Med. 2000;28(2):421-425.
Joannidis M, Kountchev J, Rauchenzauner M, et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med. 2007;33(9):1571-1579.
Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. Trans Am Soc Artif Intern Organs. 1966;12:207-209.
Kaplan AA, Petrillo R. Regional heparinization for continuous arterio-venous hemofiltration (CAVH). ASAIO Trans. 1987;33(3):312-315.
Link A, Girndt M, Selejan S, Mathes A, Bohm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009;37(1):105-110.
Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39(2):231-236.
Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005;39(10):1601-1605.
Kiser TH, MacLaren R, Fish DN, Hassell KL, Teitelbaum I. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy. 2010;30(11):1117-1126.
Bai M, Zhou M, He L, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med. 2015;41(12):2098-2110.
Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically Ill patients with acute kidney injury: A randomized clinical trial. JAMA. 2020;324(16):1629-1639.
Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2020;98(2):294-309.
Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy. Ann Intensive Care. 2020;10(1):32.
Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001;89(2):233-236.
Kindgen-Milles D, Ostermann M, Slowinski T. Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers. Crit Care. 2015;19:427.
Balik M, Zakharchenko M, Leden P, et al. Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin. J Crit Care. 2013;28(1):87-95.
Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014;9(12):2173-2188.
Ricci D, Panicali L, Facchini MG, Mancini E. Citrate Anticoagulation during Continuous Renal Replacement Therapy. Contrib Nephrol. 2017;190:19-30.
Strobl K, Hartmann J, Wallner M, Brandl M, Falkenhagen D. A target-oriented algorithm for citrate-calcium anticoagulation in clinical practice. Blood Purif. 2013;36(2):136-145.
Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2006;48(5):806-811.
Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019;23(1):22.
Khadzhynov D, Dahlinger A, Schelter C, et al. Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation. Crit Care Med. 2017;45(9):e941-e946.